<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cancer Vaccine on FinanClub</title>
    <link>https://finan.club/tags/cancer-vaccine/</link>
    <description>Recent content in Cancer Vaccine on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 23 Mar 2024 09:04:57 +0000</lastBuildDate><atom:link href="https://finan.club/tags/cancer-vaccine/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Sat, 23 Mar 2024 09:04:57 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:437
Chances: Recent publication of preclinical data in Science indicates potential for combination therapy to manage HIV without antiretroviral treatment. Phase 1 pilot study showed potential of N-803 combined with natural killer cells to reduce viral load in people living with HIV. Enrollment and initial follow-up completed for safety portions of a clinical trial studying ImmunityBioâ€™s investigational cancer vaccine and IL-15 superagonist for participants with Lynch syndrome.</description>
    </item>
    
  </channel>
</rss>
